Loading Programs

« All Events

Collaborating to Overcome Lifelong Challenges in Hemophilia A: Management of Inhibitors in Hemophilia A

November 17, 2020 - November 17, 2021

Inhibitors affect approximately 30% of patients with severe hemophilia A. In addition to substantial treatment and medical costs, patients with hemophilia who have inhibitors are twice as likely to be hospitalized for a bleeding complication. This educational activity addresses risk factors for inhibitor development, testing and monitoring strategies, the role of immune tolerance induction, and the use of bypassing agents in the setting of an inhibitor.

Jordan A. Shavit, M.D., Ph.D. Medical Oncologist, Sarcoma Oncology Center Santa Monica, CA Medical Advisor, Hemophilia Foundation of Southern California Pasadena, CA Medical Director, Orthopaedic Hemophilia Treatment Center, Los Angeles, CA

Doris Quon, MD, PhD. Associate Professor of Pediatrics  Division of Pediatric Hematology/Oncology, University of Michigan Medical School CS Mott Children’s Hospital, Ann Arbor, MI

Click here to view this activity:

https://spirelearning.realcme.com/learner/course/2749

Details

Start:
November 17, 2020
End:
November 17
Program Category:
Program Tags:
,

Organizer

Spire Learning
Phone:
(973) 605-2922
Email:
info@spirelearning.com
Website:
spirelearning.com

Other

Presenter
Jordan A. Shavit, M.D., Ph.D; Doris Quon, MD, PhD

Details

Start:
November 17, 2020
End:
November 17
Program Category:
Program Tags:
,

Organizer

Spire Learning
Phone:
(973) 605-2922
Email:
info@spirelearning.com
Website:
spirelearning.com

Other

Presenter
Jordan A. Shavit, M.D., Ph.D; Doris Quon, MD, PhD